Clinical Research Directory

Inclusion Criteria: 1. Willing and able to give written informed consent for participation in the study. 2. Diagnosis confirmed by imaging, histology, or biomarkers of one of the following: 2.1. Refractory or relapsed hematologic cancers, including acute lymphoblastic leukemia, B-cell lymphomas, or multiple myeloma; 2.2. Autoimmune diseases, including systemic lupus erythematosus (SLE), inflammatory myositis, systemic sclerosis, myasthenia gravis, multiple sclerosis, neuromyelitis optica, stiff person syndrome, demyelinating radiculoneuropathy, autoimmune encephalitis, thrombocytopenic purpura, or hemolytic anemia; or 2.3. Pre-existing anti-HLA or anti-AAV antibodies while on the wait list for organ transplantation or AAV-based gene therapy. 3. Adequate marrow, renal, and hepatic function. 4. Patients of reproductive potential (men and women) must agree to use medically accepted barrier methods of contraception (e.g., male or female condom) at the time of pregnancy testing (women of childbearing potential only), during the course of the study, and for 90 days after the last dose of study drug, even if oral contraceptives are also used. All subjects of reproductive potential must agree to use both a barrier method and a second method of birth control during the course of the study and for 90 days after the last dose of study drug. Exclusion Criteria: 1. Known active central nervous system (CNS) metastases. 2. Known hepatitis B or C or HIV infection. 3. Active infection or fever ≥38°C within 3 days of the first scheduled dose of LV009.